These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18235987)

  • 21. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
    Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
    Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
    Kamal MA; Greig NH; Alhomida AS; Al-Jafari AA
    Biochem Pharmacol; 2000 Aug; 60(4):561-70. PubMed ID: 10874131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of comparative inhibition efficiency for a novel natural ligand, galangin against human brain acetylcholinesterase, butyrylcholinesterase and 5-lipoxygenase: a neuroinformatics study.
    Shaikh S; Ahmad SS; Ansari MA; Shakil S; Rizvi SM; Shakil S; Tabrez S; Akhtar S; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):452-9. PubMed ID: 24059300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.
    Manzoor S; Prajapati SK; Majumdar S; Raza MK; Gabr MT; Kumar S; Pal K; Rashid H; Kumar S; Krishnamurthy S; Hoda N
    Eur J Med Chem; 2021 Apr; 215():113224. PubMed ID: 33582578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
    Okello EJ; Mather J
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
    Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
    ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro protection of acetylcholinesterase and butyrylcholinesterase by tetrahydroaminoacridine. Comparison with physostigmine.
    Galli A; Mori F; Gori I; Lucherini M
    Biochem Pharmacol; 1992 Jun; 43(11):2427-33. PubMed ID: 1610407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.
    Ghobadian R; Mahdavi M; Nadri H; Moradi A; Edraki N; Akbarzadeh T; Sharifzadeh M; Bukhari SNA; Amini M
    Eur J Med Chem; 2018 Jul; 155():49-60. PubMed ID: 29857276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
    Luo W; Yu QS; Kulkarni SS; Parrish DA; Holloway HW; Tweedie D; Shafferman A; Lahiri DK; Brossi A; Greig NH
    J Med Chem; 2006 Apr; 49(7):2174-85. PubMed ID: 16570913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phytochemical profiling and in vitro screening for anticholinesterase, antioxidant, antiglucosidase and neuroprotective effect of three traditional medicinal plants for Alzheimer's Disease and Diabetes Mellitus dual therapy.
    Penumala M; Zinka RB; Shaik JB; Mallepalli SKR; Vadde R; Amooru DG
    BMC Complement Altern Med; 2018 Mar; 18(1):77. PubMed ID: 29499679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
    Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
    Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
    Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives.
    Riazimontazer E; Sadeghpour H; Nadri H; Sakhteman A; Tüylü Küçükkılınç T; Miri R; Edraki N
    Bioorg Chem; 2019 Aug; 89():103006. PubMed ID: 31158577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.
    de Andrade P; Mantoani SP; Gonçalves Nunes PS; Magadán CR; Pérez C; Xavier DJ; Hojo ETS; Campillo NE; Martínez A; Carvalho I
    Bioorg Med Chem; 2019 Mar; 27(6):931-943. PubMed ID: 30765302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
    Andrisano V; Naldi M; De Simone A; Bartolini M
    Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of phenserine analogues and evaluation of their cholinesterase inhibitory activities.
    Shinada M; Narumi F; Osada Y; Matsumoto K; Yoshida T; Higuchi K; Kawasaki T; Tanaka H; Satoh M
    Bioorg Med Chem; 2012 Aug; 20(16):4901-14. PubMed ID: 22831800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
    Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
    Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinesterase inhibitors: new roles and therapeutic alternatives.
    Giacobini E
    Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.